NCT03055611 - A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B | Biotech Hunter

Enrollment

201

Participants

Timeline

Start Date

May 9, 2017

Primary Completion Date

April 19, 2022

Study Completion Date

April 19, 2022

Conditions

Haemophilia AHaemophilia B

Interventions

DRUG

ELOCTA

Extended half-life factor VIII product

DRUG

ALPROLIX

Extended half-life factor IX product

Trial Locations (22)

Swedish Orphan Biovitrum Reserach site, Berlin

Swedish Orphan Biovitrum Reserach Site, Blaubeuren Abbey

Swedish Orphan Biovitrum Research Site, Bonn

Swedish Orphan Biovitrum Research Site, Delmenhorst

Swedish Orphan Biovitrum Research Site, Duisburg

Swedish Orphan Biovitrum Reserach site, Erlangen

Swedish Orphan Biovitrum Research Site, Frankfurt

Swedish Orphan Biovitrum Reserach site, Frankfurt

Swedish Orphan Biovitrum Research Site, Fürth

Swedish Orphan Biovitrum Research Site, Hamburg

Swedish Orphan Biovitrum Research Site, Hanover

Swedish Orphan Biovitrum Reserach site, Hanover

Swedish Orphan Biovitrum Reserach site, Heidelberg

Swedish Orphan Biovitrum Reserach site, Homburg

Swedish Orphan Biovitrum Research Site, Jena

Swedish Orphan Biovitrum Reserach Site, Jena

Swedish Orphan Biovitrum Reserach site, Leipzig

Swedish Orphan Biovitrum Reserach Site, Mörfelden-Walldorf

Swedish Orphan Biovitrum Research Site, München

Swedish Orphan Biovitrum Reserach site, München

Swedish Orphan Biovitrum Reserach site, Münster

Swedish Orphan Biovitrum Research Site, Würzburg